Is three a crowd in CAR-T?
This and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast.
After talking to Derek Lowe, we preview an all-important FDA meeting about Amarin and it's fish oil-derived cardiovascular drug. Later, we talk about how Celgene might find itself on the outside looking in when it comes to CAR-T cancer therapy. Finally, in honor of STAT's fourth birthday, executive editor Rick Berke joins us to discuss the publication's origins and where it's headed.
You can listen to the episode here. To listen to future episodes, be sure to sign up on Apple Podcasts, Stitcher, Spotify, or wherever you get your podcasts.
After talking to Derek Lowe, we preview an all-important FDA meeting about Amarin and it's fish oil-derived cardiovascular drug. Later, we talk about how Celgene might find itself on the outside looking in when it comes to CAR-T cancer therapy. Finally, in honor of STAT's fourth birthday, executive editor Rick Berke joins us to discuss the publication's origins and where it's headed.
You can listen to the episode here. To listen to future episodes, be sure to sign up on Apple Podcasts, Stitcher, Spotify, or wherever you get your podcasts.
.png)
No hay comentarios:
Publicar un comentario